English
Published: 2015-01-27 07:56:32 CET
Bavarian Nordic A/S
Major shareholder announcements
Bavarian Nordic A/S - Major Shareholder Announcement
KVISTGAARD, Denmark, January 27, 2015 - Bavarian Nordic A/S (OMX: BAVA)
has
received information from A. J. Aamund A/S that the company has sold
1,793,944
shares in Bavarian Nordic and thus no longer holds any shares and
voting rights
in Bavarian Nordic.


Contacts
Rolf Sass Sørensen, Vice President
Investor Relations (EU). Phone
+45 61 77 47 43
Seth Lewis, Vice President
Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian
Nordic is an international biotechnology company developing and
manufacturing
novel cancer immunotherapies and vaccines for infectious diseases.
Lead product
candidates are PROSTVAC®, an immunotherapy product candidate for
advanced
prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical
trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3
development, which is being developed and supplied for emergency use to
the
U.S. Strategic National Stockpile under a contract with the U.S.
Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and
in the
European Union under the trade name IMVANEX. Bavarian Nordic's shares
are listed
on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO,
Bloomberg:
BAVA.DC). The company has a sponsored Level 1 ADR program listed in
the US (OTC)
under the symbol BVNRY.  For more information, visit
www.bavarian-nordic.com.

Forward-looking statements
This announcement includes
forward-looking statements that involve risks,
uncertainties and other factors,
many of which are outside of our control that
could cause actual results to
differ materially from the results discussed in
the forward-looking statements.
Forward-looking statements include statements
concerning our plans, objectives,
goals, future events, performance and/or other
information that is not
historical information. We undertake no obligation to
publicly update or revise
forward-looking statements to reflect subsequent
events or circumstances after
the date made, except as required by law.


[HUG#1889746]

 


201502uk.pdf